Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
MANHATTAN, N.Y., Sept. 12, 2017 -- Epica International, Inc., a leading robotic CT company based in San Clemente, California, recently announced the closing of a financing round with the investment group, Partners for Growth. PFG structured the $5 million term-debt facility in a key capital raise, providing growth capital to support Epica’s expansion into new markets across both imaging and robotics.
The NYC management consultancy, Facilitated Growth, acted as the key advisor on this deal, assisting in the rigorous diligence process for Epica’s five growing subsidiaries; a non-invasive CT medical imaging company, a robotics company, an advanced R&D technology center, a medical products distribution company, and a technical and scientific distribution group.
The funds are earmarked for use on growing operations, increasing the sales force, and preparing for entry into the human market. “This infusion of capital will assist us in furthering our goals to integrate CT imagery with precision robotics and ultimately deliver the future of medical diagnosis and therapy,” said Epica CEO, Frank D’Amelio.
Contact Info: Joe Soto, Facilitated Growth, [email protected], 212-697-1316
